Ashling Wahner

Associate Editor, OncLive

Ashling Wahner joined MJH Life Sciences in 2022. She produces OncLive's podcast, OncLive On Air, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Articles

Education, Proactive Management Are Key to Navigating Ocular Toxicities and Other ADC-Related AEs in Breast Cancer

October 31st 2025

Komal Jhaveri, MD, FACP, discusses management strategies for ocular toxicities and other ADC-related adverse effects in breast cancer.

Early Detection, Surgical Innovation, and Multidisciplinary Collaboration Evolve Lung Cancer Care: With Ziad Hanhan, MD, Thomas Bauer, MD, and Rachel NeMoyer, MD

October 30th 2025

Drs Hanhan, Bauer, and NeMoyer discuss the ins and outs of lung cancer diagnosis, surgical management, and evolving treatment paradigms.

Dr Hurvitz on Data With Gedatolisib-Based Regimens in PIK3CA Wild-Type HR+/HER2-Negative Breast Cancer

October 30th 2025

Sara A. Hurvitz, MD, FACP, shares efficacy and safety data from the VIKTORIA-1 study in endocrine-resistant HR-positive breast cancer.

Dr Hurvitz on the Rationale for Targeting PI3K and mTOR in PIK3CA Wild-Type HR+/HER2-Negative Breast Cancer

October 30th 2025

Sara A. Hurvitz, MD, FACP, explains the clinical rationale for targeting the PI3K/mTOR pathways with gedatolisib in the VIKTORIA-1 trial.

Dr Jänne on Key Areas of Ongoing Debate in EGFR+ NSCLC

October 30th 2025

Pasi A. Jänne, MD, PhD, discusses key areas of debate in lung cancer management, with a focus on defining the optimal duration of adjuvant targeted therapy.

Dr Le on Innovations and Future Directions for KRAS Inhibition in NSCLC

October 30th 2025

Xiuning Le, MD, PhD, discusses the current landscape of KRAS G12C inhibitors and emerging strategies for optimizing KRAS inhibition in NSCLC.

Advances in EGFR+, HER2-Mutant, and CNS-Involved NSCLC Dominate Discussion After ESMO 2025

October 30th 2025

Experts highlight pivotal data in EGFR- and HER2-mutant NSCLC from the 2025 ESMO Congress, including updates on ADCs, TKIs, and real-world outcomes in LMD.

Dr Tarantino on Clinical Implications of the neoCARHP Trial in HER2+ Breast Cancer

October 30th 2025

Paolo Tarantino, MD, PhD, discusses the clinical utility of data from the phase 3 neoCARHP trial in patients with HER2-positive early breast cancer.

Dr Visco on the Role of RBAC Dose Reductions for High-Risk MCL

October 30th 2025

Carlo Visco, MD, highlights the clinical relevance of reducing the dose of certain RBAC components when administering this regimen in high-risk MCL.

Dr Randall on Incorporating Ultrasound STS Surveillance Into Clinical Practice

October 30th 2025

R. Lor Randall, MD, FACS, discusses a new STS surveillance algorithm based on findings that show the comparable diagnostic utility of ultrasound and MRI.

ESMO 2025 GI Cancer Data Highlight Emerging Precision Strategies and Treatment Avenues for Rare Cancers

October 30th 2025

Revisit the most intriguing GI cancer data from the 2025 ESMO Congress.

Evolving Research Paradigms, Real-World Data, and Multidisciplinary Collaboration Enhance Bladder Cancer Management: With Amit Mehta, MD

October 29th 2025

Amit Mehta, MD, discusses practice-changing urothelial carcinoma data that have been presented throughout 2024 and 2025.

Dr Mouhieddine on Future Directions With Ferritin and ALC as Biomarkers in Myeloma

October 28th 2025

Tarek Mouhieddine, MD, discusses future research directions with ferritin and ALC as biomarkers of response to bispecific antibodies in myeloma.

Dr Lee on the Role of SABR in Non–Small Cell Lung Cancer Management

October 28th 2025

Percy Lee, MD, discussed the use of SABR within the larger radiation therapy paradigm for the management of non–small cell lung cancer.

FDA Approval Insights: Y-90 Resin Microspheres for Unresectable HCC: With Armeen Mahvash, MD

October 27th 2025

Dr Mahvash discusses the FDA approval of SIR-Spheres Y-90 resin microspheres for the treatment of patients with unresectable hepatocellular carcinoma.

Serial ctDNA Testing Holds Potential to Further Personalize MIBC Management

October 27th 2025

Joaquim Bellmunt, MD, PhD, discusses ways that ctDNA tests could augment bladder cancer management and the need for confirmatory data from ongoing trials.

ESMO 2025 Breast Cancer Data May Redefine Treatment Standards Across Patient Subgroups

October 27th 2025

Revisit the top data and presentations in breast cancer from the 2025 ESMO Congress.

Gedatolisib-Based Regimens May Advance PIK3CA Wild-Type Metastatic Breast Cancer Care

October 27th 2025

Sara A. Hurvitz, MD, FACP, discusses the design of VIKTORIA-1, key efficacy and safety findings, and how these data may influence breast cancer management.

IMvigor011 Confirms ctDNA Status as Key Predictor of Adjuvant Atezolizumab Efficacy in MIBC

October 24th 2025

Joaquim Bellmunt, MD, PhD, discusses the rationale for and findings from the IMvigor011 trial of ctDNA-guided adjuvant atezolizumab vs placebo in MIBC.

International Medical Graduates Produce Significant Research Contributions During Hematology/Oncology Fellowship

October 24th 2025

Arya Mariam Roy, MD, MBBS, discusses a study of the research productivity of hematology/oncology fellows who are international medical graduates.